Maximum neutralization activity of bnMAbs in a TZM-bl target cell assay. by Laura E. McCoy (386535)

“…<p>(A) The bnMAbs are ordered from left to right according to decreasing medians of MPN. Each point on the graph represents the percent at which the neutralization curve plateaued for a single virus. …”

Comparison of <i>Killer-Rescue</i> and split <i>ClvR</i> genetics. by Georg Oberhofer (3401438)

P1- and P2-mediated delivery of DOX escapes cardiotoxicity associated with free DOX administration. by Sibu P. Kuruvilla (4382191)

“…Further, free DOX mice had a 100% death rate by day 15, while P1- and P2-treated had a 100% survival rate during the monitoring period. …”

Optimizing the Void Size of Yolk–Shell Bi@Void@C Nanospheres for High-Power-Density Sodium-Ion Batteries by Hai Yang (1646371)

“…The Bi@Void@C-2 shows an excellent rate capacity of 173 mA h g^–1 at ultrahigh current density of 100 A g^–1 and long-cycle life (198 mA h g^–1 at 20 A g^–1 over 10 000 cycles). …”

Optimizing the Void Size of Yolk–Shell Bi@Void@C Nanospheres for High-Power-Density Sodium-Ion Batteries by Hai Yang (1646371)

“…The Bi@Void@C-2 shows an excellent rate capacity of 173 mA h g^–1 at ultrahigh current density of 100 A g^–1 and long-cycle life (198 mA h g^–1 at 20 A g^–1 over 10 000 cycles). …”

MVATG18598 immunization triggers Mtb antigen-specific cells producing IFNγ and induces cells with antigen-specific cytolytic activity. by Stéphane Leung-Theung-Long (830219)

Glycolysis induced by SVA infection inhibits RLR signaling. by Huizi Li (6241586)

RLR signaling was inhibited by SVA through lactate in mice. by Huizi Li (6241586)

Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

A binding mode landscape for disordered protein interactions. by Attila Horvath (285787)

“…Context-dependent <b>disorder-to-order</b> binding is exemplified by the <b>polymorphic interactions</b> of the ribosomal S6 kinase 1 (RSK1, residues 697–703, <i>light blue dots</i>), which adopts different secondary structures upon binding to S100B, corresponding to autoinhibited and active forms (PDB:5csf, 5csi, 5csj [<a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1007864#pcbi.1007864.ref023" target="_blank">23</a>]). …”

Effect of MMP9 on phFAK and ILK expression. by Nabila Djaziri (17537499)

“…<p>(A, B) Comparative phFAK expression in jck-MMP9+/+ and jck-MMP9-/- kidneys. …”

Association of covariates and COPD risk. by Yushan Shi (16440272)

“…</p><p>Conclusion</p><p>Our findings suggest a potential link between increased dietary niacin intake and a decreased prevalence of COPD.…”

<i>upd3</i> loss-of-function mutations suppress the synthetic lethal phenotype of <i>Gpdh1</i>^{<i>A10/B18</i>}<i>; Ldh</i>^<i>16/17</i> double mutants. by Madhulika Rai (4352803)

Bidirectional grey-matter CBF changes induced by a hypercapnic challenge. by Juliana Zimmermann (10507091)

Lactate produced by SVA-induced glycolysis inhibits RLR signaling. by Huizi Li (6241586)

Examination of mitochondrial function and cell viability in <i>PLA2G6</i>-KD cells. by Goichi Beck (818821)

“…(B) Expression levels of CCO are decreased in <i>PLA2G6</i>-KD cells compared with those of SH-SY5Y cells treated with negative control siRNA with statistical significance (*<i>p < 0</i>.…”